Bridges Investment Management Inc. Sells 58,619 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bridges Investment Management Inc. cut its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 77.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,628 shares of the medical research company's stock after selling 58,619 shares during the period. Bridges Investment Management Inc.'s holdings in Edwards Lifesciences were worth $1,097,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Crewe Advisors LLC bought a new position in Edwards Lifesciences during the 1st quarter valued at about $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at about $29,000. Webster Bank N. A. acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $39,000. Peoples Bank KS bought a new stake in Edwards Lifesciences during the 3rd quarter worth about $40,000. Finally, Versant Capital Management Inc raised its stake in shares of Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company's stock worth $45,000 after buying an additional 326 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Daveen Chopra sold 1,250 shares of the company's stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,133,916.72. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,250 shares of company stock valued at $2,746,988. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Up 0.6 %

Shares of EW traded up $0.39 during mid-day trading on Friday, reaching $66.23. 3,088,441 shares of the company were exchanged, compared to its average volume of 5,173,085. The business has a 50 day simple moving average of $67.59 and a two-hundred day simple moving average of $76.89. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The stock has a market capitalization of $39.06 billion, a PE ratio of 9.56, a PEG ratio of 3.70 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 22.56%. The company's revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 EPS. On average, analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of a number of recent analyst reports. Daiwa Capital Markets upgraded Edwards Lifesciences from a "neutral" rating to an "outperform" rating in a report on Wednesday, July 31st. Royal Bank of Canada dropped their price objective on Edwards Lifesciences from $85.00 to $75.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Bank of America cut shares of Edwards Lifesciences from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $105.00 to $75.00 in a research report on Thursday, July 25th. Baird R W lowered shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 25th. Finally, TD Cowen cut Edwards Lifesciences from a "buy" rating to a "hold" rating and decreased their price target for the stock from $100.00 to $70.00 in a research report on Thursday, July 25th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.